Home/Filings/4/0001415889-24-003637
4//SEC Filing

Forman Mark S 4

Accession 0001415889-24-003637

CIK 0001787297other

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 7:34 PM ET

Size

16.0 KB

Accession

0001415889-24-003637

Insider Transaction Report

Form 4
Period: 2021-08-16
Forman Mark S
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Unit

    2024-02-105,00010,000 total
    Common Stock (5,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2021-08-16+130,000130,000 total
    Exercise: $10.84Exp: 2031-08-15Common Stock (130,000 underlying)
  • Award

    Restricted Stock Unit

    2022-02-10+15,00015,000 total
    Common Stock (15,000 underlying)
  • Exercise/Conversion

    Common Stock

    2024-02-10+5,00050,269 total
  • Sale

    Common Stock

    2024-02-13$0.97/sh1,638$1,58948,631 total
  • Award

    Employee Stock Option (right to buy)

    2022-02-10+25,00025,000 total
    Exercise: $4.52Exp: 2032-02-09Common Stock (25,000 underlying)
Footnotes (5)
  • [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  • [F2]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
  • [F3]The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F4]The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F5]1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Issuer

Passage BIO, Inc.

CIK 0001787297

Entity typeother

Related Parties

1
  • filerCIK 0001922353

Filing Metadata

Form type
4
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 7:34 PM ET
Size
16.0 KB